Eisai Inactive Page Revenue and Competitors
Estimated Revenue & Valuation
- Eisai Inactive Page's estimated annual revenue is currently $724M per year.
- Eisai Inactive Page's estimated revenue per employee is $201,000
Employee Data
- Eisai Inactive Page has 3602 Employees.
- Eisai Inactive Page grew their employee count by 2% last year.
Eisai Inactive Page's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Medical Officer, SVP, Head Global Medical Affairs, Neurology | Reveal Email/Phone |
2 | Executive Assistant to VP, Integrated Oncology Data Services (DHBL) | Reveal Email/Phone |
3 | Chief Staff to the Chairman & CEO | Reveal Email/Phone |
4 | Sr. Executive Assistant to EVP Human Resources, Chief Strategy Officer & Exec Dir Total Rewards | Reveal Email/Phone |
5 | VP, Alzheimer’s Disease Commercial | Reveal Email/Phone |
6 | SVP | Reveal Email/Phone |
7 | VP, Corporate Planning | Reveal Email/Phone |
8 | Head Clinical Biomarker, Translational Science | Reveal Email/Phone |
9 | VP, Business Innovation & hhceco Transformation | Reveal Email/Phone |
10 | VP, Global Head Clinical Operations | Reveal Email/Phone |
Eisai Inactive Page Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 25 | -11% | N/A | N/A |
#2 | $35.8M | 178 | 8% | N/A | N/A |
#3 | $5.4M | 27 | -25% | N/A | N/A |
#4 | $4180M | 14516 | 1% | $550M | N/A |
#5 | $12.5M | 62 | 15% | N/A | N/A |
#6 | $6.7M | 119 | -37% | $199.6M | N/A |
#7 | $9.4M | 47 | 7% | N/A | N/A |
#8 | $10.3M | 51 | 6% | N/A | N/A |
#9 | $106.3M | 529 | 16% | N/A | N/A |
#10 | $15.5M | 77 | 20% | N/A | N/A |
What Is Eisai Inactive Page?
Thank you for your interest in Eisai Inc. This page is not active, please go to the Eisai US page for the latest job postings and company information.
keywords:N/A
N/A
Total Funding
3602
Number of Employees
$724M
Revenue (est)
2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Eisai Inactive Page News
Fosgonimeton (also known as ATH-1017), contains an inactive molecule, ... to fosgonimeton were pain and itching at the injection site.
Co-developed by Biogen and Eisai, the therapy received accelerated ... that in many trials some participants are given an inactive placebo,...
... was approved by an institutional review board at each participating site. ... Silicon Therapeutics, Nuvalent, Inc, Eisai, Bayer, Syndax,...
Markets in Japan were closed Thursday for the spring equinox, but shares of Eisai were trading Friday morning at $54 each on the US over-the-counter market, down from $81 on Thursday at midday. On Thursday, Biogen and Eisai announced they would discontinue clinical development of aducanumab, an ...
Other Companies in Woodcliff Lake
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2439.4M | 5280 | 19% | N/A |